Blood Safety Around the World
Keywords:
-Abstract
-
Downloads
References
Safe blood starts with me. WHO-Geneva 2000:8.
Strategies for safe blood transfusion. Motivation, Recruitment and Retention of blood donors; Quality Management in Blood Transfusion Service. WHO-SEARO, 1998 SEA/HLM/311,5-17:47-54.
Weber Bernard. Laboratory Diagnosis of HIV Infection: role of Combined HIV p24 Antigen and Antibody assays. J Lab Med 2001:25:226-31.
Bharucha ZS. Risk Management Strategies for HIV in Blood Transfusion in Developing countries. Vox Sang 2002:23(Suppl.1):167-70.
Dhingra Neelam. Blood safety in the developing world and WHO Initiatives. Vox Sang 2002;83(Suppl.1):173-7.
Hewlett IK, Epstein JS. Food and Drug Adminitration Conference on the Feasibility of Genetic Technology to use the HIV Window in Donor Screening. Transfusion 1997;37:352-3.
Gallarda Jamu L, Dragon Elizabeth. Blood Screening by Nucleic Amplification Technology: Current Issue. Future Challenges. Molecular Diagnosis 2000:5:11-20.
Corash L. Inactivation of viruses, bacteria protozoa and leukocyts in platelet concentrates. 199874(Suppl 2):173-6.
Hillyer CD, Landford KV, Roback JD, et al. Transfusion of the HIV seropositive patient immunomodulation, viral reactivation and limiting exposure to EAVm CMV and HHV 6, 7 and 8 transfusion medicine review 1999;13:1-17.
Symposium at AABB on Advancing Blood Safety Worldwide, Outlook on Blood Safety. Winter 2001;3.1:1.
Faber Jean-Claude. Haemovigilance around the world. Vox Sang 2002;83(Suppl.1):71-6.
Strategies for Safe Blood Transfusion. Screening of blood WHO SEARO 1998:18-23.
Blood Safety and Clinical Technology Strategy 2000-2003. WHO Geneva: 2-3.
Van Gemen B, Kievits T, Schukkink R, et al. Quantification of HIV-1/ RNA in plasma using NASBA during HIV-1 primary infection. J Viral Meth 1993;43:177-87.
Benjamin Richard J. Nucleic Acid Testing: Update and Applications, Seminar in Hematology 2001;37 (suppl 9):12-4.
Le Corfec E, Le Pont F, Treckivell HC, et al. Direct HIV Testing in Blood Donation: Variation of the Yield with Detection Threshold and Pool Size. Transfusion 1999.39:1141-4.
Both WK, Buhr, Dresten C, et al. NAT and Viral Safety in Blood Transfusion. Vox Sang 2000:78(suppl 2):257-9.
Report of Interorganizational Task Force on Nucleic Acid Amplification of Blood Donors. Transfusion 2000; 40:144-53.
Quinn TC, Brookmeyer R, Kline R, Shepherd M, Paranjape R, Mechendale S, Gadkari DA, Bolliger R. Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence. AIDS 2000;14:2751-7.
Gurtler L, Muhlbacher A, Michl U, Hofmunntt, Malchior W. Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assays. J Viral Meth 1998;75:27-38.
Ly TD, Laperche S, Courouer AH. Early Detection of Human Immunodeficiency Virus Infection Using Third and Fourth-Generation Screening Assays. Eur J Clin Microbial Infect Dis 2001;20:104-10.
Weber B, Fall EHM, Berger A, Daerr HW. Reduction of window by fourth generation human immunodeficiency virus screening assay. J Clin Microbio 1998:36:2235-9.
Tanprasert S, Chiewsilp P, Tira Watnapong, Oota S. NAT Screening of Infectious Markers feasible in Thai Blood Donors; Oral presentation Vancouver ISBT 2002, August 24-29.
Dodd - Royer Y. Pathogen Inactivation: Mechanisms of action and in vitro Efficacy of Various Agents. Vox Sang 2002:83(Suppl 1):267-70.
Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman S, Shulman RW. Solvent/detergent-treated plasma; A virus-inactivated substitute for fresh frozen. Blood 1992:79.826-31.
Muller-Breikreutz K, Mohr H. Hepatitis C and human immunodeficiency virus RNA degradation by methylene blue/light treatment of human plasma. J Med Virol 1998;56:239-45.
Bernade LE, Shumaker J, Xu Y, Chin X, Dodd RY. Inactivation of free and cell associated human immunodeficiency virus in platelet suspension by aminome-thytrimethyl psoralen and ultraviolet light. Transfusion 1994;34:680-4.
Wagner SJ, Skripchenko A, Pugh JC, Suchmann DB, Ijaz MK. Duck hepatitis B photoinactivation by demethyl metylene blue in RBC suspensions, Transfusion 2001;41:1154-8.
Corash L, Lin L, Weisehaln G. Use of 8. Methoxypsoralen and long wavelength ultraviolet radiation for decontamination of platelet concentrates. Blood Cells 1992;18:57-74.
Moroff G, Wagner S, Benade L, Dodd RY. Factors influencing virus inactivation and retention of platelet properties following treatment with aminomethytrimethyl psoralen and ultraviolet A light. Blood Cells 1992;18:43-56.
Wagner SJ, Bardossy L, Moroff G, Dodd RY, Blajchman MA. Assessment of the hemostatic effectiveness of human platelets treated with aminomethyltrimethyl psoralen (AMT) and ultraviolet A light (UVA) using a rabbit ear bleeding time technique Blood 1993;82:3489-92.
AuBuchon James P. Pathogen inactivation in cellular blood components: Clinical Trials and Implications of Introduction to Transfusion Medicine. Vox Sang 2002;83(Suppl 1):271-5.
Lin L. Inactivation of cytomegalovirus in platelet concentrates using Helinx technology: Seminar Hematol 2001;38(suppl 11):27-33.
Luban NLC. Prevention of transfusion associated graft-versus-host disease by inactivation of T cells in platelet components. Semin Hematol 2001:38(Suppl 11):34-45.
Wollowitz S. Fundamenteds of the psoralen-based Helinx technology for inactivation of infections pathogens and leukocytes in platelets and plasma. Semin Hematol 2001,38(suppl 11):4-11.
Klein HG.ed. Standard for blood bank and transfusion services 17th ed Bathesda, MD. American Association of Blood Banks, 1996.
Humbat JR, Flesmin CD, Winsor EL. Early damage to granulocytes during storage. Semin Hematol 1991;28:10-3.
Heaton A. Timing of leukodepletion of Blood products. Semin Hematol 1991:28:1-2.
Blajchman MA. The effect of leukodepletion on allogeneic donor platelet survival and refractoriness in animal model. Semin Hematol 1991:28:14-7.
American Association of Blood Banks. Technical manual. 12th edition. Administration of Blood and Components, Washington D.C. 1996:451.
Lutz, Dzik WH. Large volume hemocytometer chamber for accurate counting of white cells (WBC's) in WBC-reduced platelet: Validation and applicalion for quality control of WBC-reduced platelets by apheresis and filtration. Transfusion 1993;331:409-12.
Vacula M, Simpson SJ, Martension JA, et al. A flow cytometic method for counting very low levels of while cells in blood and blood components. Transfusion 1993:33:262-7.
Brecher Mark E.Bacterial Contamination of Blood Products, Symposium at AABB on Advancing Blood Safety Worldwide 2000, Outlook on Blood Safety, Winter 2001;3.1:4-5.
Hashimoto Hiroshi. Prevention of Bacterial Contaminatioin in Blood Components, Securing safe blood, The Third Red Cross and Red Crescent Symposium on Blood Program in the Asian Region 2001:176-83.
Goldman Mindy. Challenges in Developing a Bacterial Detection System. Vox Sang 200283(suppl 1):125-7.
Engefriet CP, Reesink HW. Haemovigilance System. Vox Sang 1999;77:110-20.
Serious Hazards of Transfusion Annual Report 2000-2001, ISBN Number 09532 789 48.
Williamson Lorna M. Using Haemovigilance data to set Blood Safety Priorities. Vox Sang 2002;83(suppl 1):065-9.
Todd Audrey. Haemovigilance - closing the loop. Vox Sang 2002483(suppl 1):013-6.
Faber Jean-Clande. Haemovigilance around the World. Vox Sang 200283(Suppl.1):071-6.
ศรีวิไล ตันประเสริฐ. Quality and Adequacy in Transfusion Service, คำบรรยายการประชุมใหญ่วิชาการประจำปี 2544 ISBN 974-8226-39-5:1-11.
Lin Che Kit. Quality System in Blood Transfusion Service Hongkong Experience, Proceedings Securing Safe Blood IIl, The Third Red Cross and Red Crescent Sysmposim in the Asian Region 2001:248-80.
Country Report I-V-The Progress/Change in three years, Proceedings Securing Safe Blood III, The Third Red Cross and Red Crescent Symposium in the Asian Region 2001:27-130.
Adeeryi JO. The Challenge of Blood Safety in Africa, Transfusion Clinique Et Biologique 2001;8(Suppl.1):225.
Allain JP, Adarkwa M, Sarkodie F, Owusu-Ofori S, Predonation Screening: Improving Cost-Efficiency in Resource Poor, Highly Endemic Areas, Transfusion Cliniqkue Et Biologique 2001;8(Suppl.)225-33.
Recruitment of Blood Donors in an HIV Endemic Area, VI Regional European Congress of the International Society of Blood Transfusion, Yarusalem, Isarael, May 9-13,1999:62a-62b.
Diane deconing, Challenge Facing Donor Recruitment in South Africa Vox Sang 2002;83(Suppl):237-41.
United States General Accounting Office. Blood Plasma Safety: Plasma product risks are low of good manufacturing practice are Followed, 1998; GAO/HEHS 98-205, 1-45 Washington DC, GAO.
Advances in Transfusion Safety- 2002. Transfusion Today, June 2002 ISSN:1015-3276.
Committee for Proprietary Medicinal Products: The Application of Genome Amplification Technology (GAT) to plasma fractionation pools CPMP/BWP/390/97(rev 6).
F'lesland O, Krusires T, Gudmundsson S, Safwenbarg J, Jorgensen J. NAT Testing in the Nordic Countries. Vox Sang 2002;83(Suppl 2):39.
Jorgensen J. NAT Testing in the Nordic Countries. Vox Sang 2002;83(suppl 2):39.
Choong Lai Hock, Lam Sally, Lale Suma, Teo Diana. HCV NAT Testing of Singapore Blood Donors. Vox Sang 2002;83(suppl.2):42.
Countries with 100% Leukocyte Reduction Mandate. Outlook on Blood Safety. Winter 2001;3.1:10.
Masse M. Universal Leukoreduction of Cellular and Plasma Components: Process control and performance of the leukoreduction Precess. Transfusion Clin Biol 2001;8:297-302.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
